Clinical Trial: Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07198464) titled 'Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma' on Sept. 22.

Brief Summary: To evaluate the efficacy and safety of relmacabtagene autoleucel combined with autologous hematopoietic stem cell transplantation, orelabrutinib, and sintilimab as first-line or relapsed/refractory treatment for primary central nervous system diffuse large B-cell lymphoma.

Study Start Date: Oct. 07

Study Type: INTERVENTIONAL

Condition: Primary Central Nervous System Lymphoma (PCNSL)

Intervention: DRUG: Relmacabtagene autoleucel and tran...